Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | Optimal time for allo-HSCT in AML

Ivan Moiseev • 30 Aug 2020
EBMT 2020
Acute Myeloid Leukemia Leukemia

Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, talks on the optimal time for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult patients with acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ivan Moiseev

Significance of MRD negativity in Ph-negative ALL
1:01
Significance of MRD negativity in Ph-negative ALL
Ivan Moiseev • 1 Sep 2020
GO-FLAG: bridge therapy to allo-SCT in R/R AML
0:53
GO-FLAG: bridge therapy to allo-SCT in R/R AML
Ivan Moiseev • 30 Aug 2020
Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL
1:27
Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL
Ivan Moiseev • 1 Sep 2020
Mutational profiles of MDS patients undergoing allo-HSCT
1:29
Mutational profiles of MDS patients undergoing allo-HSCT
Ivan Moiseev • 30 Aug 2020

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Ivan Moiseev • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Ivan Moiseev • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Ivan Moiseev • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Ivan Moiseev • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals